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ABSTRACT
Sequence analysis of the Sall g region of the genome
of a virulent isolate of ASFV (Malawi Lil 20/1) has
revealed an open reading frame with the potential to
encode a 48 kilodalton (kD) polypeptide which has
significant homology with eukaryotic and prokaryotic
DNA ligases. This ASFV encoded gene also contains
the putative active site region of DNA ligases including
the lysine residue which is necessary for enzyme-
adenylate adduct formation, but lacks the C-terminal
basic region conserved in other eukaryotic DNA
ligases. A novel [32P]-labelled potential DNA ligase-
adenylate adduct of Mr 45 kD was observed upon
incubation of ASFV infected cell cytoplasmic extracts
with a-[32P]-ATP and subsequent analysis of products
by SDS/PAGE. These data together suggest that ASFV
encodes its own DNA ligase.
INTRODUCTION
African swine fever virus (ASFV) is a large icosahedral
deoxyribonucleic acid containing virus which replicates in the
cytoplasm of infected cells [for reviews see (1 -3)] and is
classified as the only member of a separate virus family (4). The
pattern of ASFV gene expression is temporally regulated and
early, early/late and late classes of induced proteins are
synthesised in infected cells (5,6). In common with the
poxviruses, a cytoplasmic site of viral replication necessitates that
ASFV encode many of the enzymes required for mRNA
transcription and DNA replication. Some of these enzymes are
packaged into ASFV particles, such as a DNA topoisomerase
(7) and those required for early gene expression such as a DNA-
dependent RNA polymerase (8) and mRNA capping, methylation
and polyadenylating enzymes (9). Other enzyme activities are
induced in ASFV infected cells (3). The genes encoding
thymidine kinase (10), both the large and small subunits of
ribonucleotide reductase (11) and of a ubiquitin conjugating
enzyme (12), have so far been identified on the ASFV genome.
EMBL accession no. X65192
The sequence of vaccinia virus DNA ligase has been reported
(13) and is the only mammalian virus-encoded DNA ligase
identified until now. It was predicted that ASFV should also
encode its own DNA ligase because of its cytoplasmic site of
replication, and similar genome structure and mode of replication
to poxviruses. DNA ligases join single strand breaks in double
stranded DNA by catalyzing the formation of phosphodiester
bonds and require a divalent metal ion and either ATP or
NAD+ as co-factor. They play a major role in joining Okazaki
fragments produced during lagging strand DNA synthesis, sealing
nicks in repaired DNA and completing recombination events by
joining 'crossed over' DNA strands (14,15).
This report describes the identification and primary structure
of an African swine fever virus gene encoding a 419 amino acid
polypeptide of predicted molecular weight 48 kD with amino acid
sequence homology to DNA ligases. In addition, the gene is
shown to encode a Mr 45 kD protein which forms a
[32P]-labelled adduct, an intermediate in the DNA ligase
reaction mechanism, after incubation with a-_[32P]-ATP. A
similar protein is present in cytoplasmic extracts ofASFV infected
cells.
MATERIALS AND METHODS
Nucleotide sequencing
A 4.2 kb DNA fragment from within the Sall g fragment of the
Malawi Lil 20/1 strain of ASFV was isolated from SalI/BamHI
restricted bacteriophage lambda clone LMw16 (16) (fig 1). This
fragment was inserted into the bluescript SK+ plasmid
(Stratagene) and digested with exonuclease IH and SI nuclease
to obtain a nested set of deletions for nucleotide sequence analysis
(17). Double stranded DNA was sequenced using the M13
reverse primer (18). The second strand was sequenced using
15-mer oligonucleotide primers determined from the first strand
sequence, spaced approximately 200 nucleotides apart. The
nucleotide sequence data were assembled into contiguous
sequences using the programmes DBAUTO and DBUTIL (19).
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The deduced amino acid sequence of the encoded open reading
frame (ORF) was compared with the SWISSPROT protein
database and multiple protein sequences aligned using the
programme Gap (20).
Assay for the formation of DNA ligase-AMP adduct in ASFV-
infected cells
Porcine kidney RSII cells were infected with a tissue-culture
adapted Ugandan isolate of ASFV at a multiplicity of infection
of 10. Cells were harvested at various times post infection and
extracts labelled with Oa-[32P]-ATP (21,22). DNA ligase-AMP
adduct formation was visualised by 12.5% SDS polyacrylamide
gel electrophoresis (SDS/PAGE) of products followed by
autoradiography of the dried gels.
Cloning of the ASFV gene in an expression vector
The coding region of the putative ASFV DNA ligase gene was
amplified by the polymerase chain reaction (PCR) and inserted
into KS+ bluescript (Stratagene) to enable expression of the
gene under the control of the T7 RNA polymerase promoter.
Oligonucleotide primers used in the PCR were 5' TTTTCTG-
CAGGGATCCTCATGCTAAGTCAATTTCCT 3' and
5' TTTTAAGCTTGAATTCTTAAATAATTTCTAAAACGT 3'
and included a PstI restriction site upstream of the ATG start site
and a Hindm site downstream of the stop codon (sites are
underlined). The template DNA used in PCR reactions was the
plasmid subclone used for sequencing and reactions were carried
out for 25 cycles of 2 minutes at 92°C, 2 minutes at 45°C and 3
minutes at 72°C. After amplification the PCR product was digested
with PstI and HindU and inserted into PstIIHindIII restricted KS+.
The resultant plasmid is referred to as KS+lig.
Expression of the putative ASFV DNA ligase gene in E. coli
E. coli BL21 pLysS (23) were transformed with KS+lig and
expression of the putative ASFV DNA ligase gene induced by
the addition of 2mM isopropylthio-B-galactosidase (IPTG).
Bacterial extracts were prepared in ligase extraction buffer (21)
by sonication and assayed for the formation of a DNA ligase-
AMP adduct as above.
RESULTS
Sequence analysis of the ASFV encoded DNA ligase
A 4.2 kb SalI/BamHI fragment was excised from bacteriophage
lambda clone LMw16 (16), which contains sequences from the
SalI g fragment of ASFV isolate Malawi Lil 20/1 (fig la and
lb), and inserted into bluescript SK+ for sequence analysis. A
contiguous DNA sequence of 4,138 nucleotides was obtained.
Translation of this sequence revealed one complete ORF flanked
by two incomplete ORF's (fig 1c). The complete ORF covers
1257 nucleotides from position 1778 to 3034 on the SalI/BamHI
fragment and encodes a potential polypeptide of 419 amino acids
with a predicted molecular weight of 48 kD (SalIg 48 kD ORF).
Computer database searches against the SWISSPROT protein
library indicated that the 419 amino acid polypeptide shared
significant homology with vaccinia virus DNA ligase. Using the
programme FASTA (24) with a ktup value of one, an optimised
score of 146 was obtained with 20.9% identity in a 292 amino
acid overlap.
Table 1 shows a comparison of the predicted molecular weight
and percentage identity of the putative ASFV DNA ligase with
other DNA ligases which utilise ATP as co-factor. There is great
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Figure 1. Genome location of ASFV encoded DNA ligase. (a) The SalI map
of the complete genome of the ASFV Malawi Lil 20/1 isolate. (b) The Sall g
fragment is expanded and the position of the 4.2 kb fragment excised from clone
LMw16 (16) is indicated. (c) This 4.2 kb fragment is expanded and the position
and direction of ORF's encoded on this fragment are indicated by arrows.
variation in size between the DNA ligases attributed to the highly
variable length of the amino terminal region upstream of the active
site (25). In contrast the carboxy termini appear well conserved
in length and sequence. The bacteriophage T3 enzyme comprises
346 amino acids and has a predicted molecular weight of 39 kD
(26) whereas the human DNA ligase I is a 102 kD polypeptide
comprising 919 amino acids (27). Due to the highly variable
nature of the N-terminal regions of the DNA ligases, companisons
were carried out using both full length sequences and sequences
extending towards the C-terminus from the predicted active site
lysine. Comparisons over the complete amino acid sequence
indicated that the SalIg 48 kD ORF had between 20%
(bacteriophage T7) and 25% (bacteriophages T3, 4 and 6)
(26,28-30) amino acid identity with all DNA ligases examined
(data not shown). The putative ASFV DNA ligase was closest
in size and had highest homology with bacteriophage T4 and T6
DNA ligases. A comparison of the known DNA ligase active
site (25) and the probable corresponding lysine residue of other
DNA ligases, demonstrated that the ASFV polypeptide contains
a conserved potential active site region (table 2). The lysine
residue predicted to be involved in enzyme-adenylate adduct
formation is at position 151. If this lysine is the reactive residue,
then its distance from the carboxy terminus, 268 amino acids
(table 1), is 44 amino acids shorter than the previously reported
conserved terminal region of 332 (+/- 20) residues for all other
eukaryotic DNA ligases (25). Including the lysine at position 151,
3 of the next 6 amino acids are identical to those in all eukaryotic
DNA ligases at their active sites, with a conservative change
(aspartic acid for an asparagine) at a fourth residue 153.
Alignment of sequences from the presumed active sites to the
carboxy termini showed that this was the most conserved portion
of the enzyme and in this region bacteriophage T4 DNA ligase
has the highest percentage amino acid identity (32%) when
compared with the ASFV DNA ligase (table 1). Figure 2 shows
the complete amino acid sequence of the putative ASFV DNA
ligase and its alignment from the predicted active site lysine with
I
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Table 1. Comparison of amino acid sequences of DNA ligases.
(a) (b) (c) (d) (e) (f) (g)
DNA LIGASE No. of amino acids M.WT kD Position of predicted Distance from lysine % similarity from % identity from
active site lysine to C-terminus lysine to C-terminus lysine to C-terminus
from N-terminus
ASFV 419 48 151 268
PT3 346 39.3 34 312 47 26
PT7 359 41.1 34 325 47 21
PT6 487 55.3 159 328 50 25
PT4 487 55.3 159 328 58 32
VV 552 63 231 321 48 22
S.CER 755 84.8 419 336 52 25
HUMAN 919 101.7 568 351 47 21
In panel (a) the source of the DNA ligase gene is indicated: ASFV, bacteriophage T3, T4, T6 and T7 (PT3 to PT7 respectively), vaccinia virus (VV), Saccharomyces
cerevisiae (S. cer) and human DNA ligase I (Human) (13,26-31). The number of amino acids in each sequence (b), and the predicted molecular weight of encoded
proteins (c) are shown. The predicted position of the active site lysine (d) and the number of amino acids between this lysine and the carboxy terminus (e) are indicated.
The percentage of similar (f) and identical (g) amino acids are shown after alignment of each DNA ligase sequence with the ASFV DNA ligase from the active
site lysine to the C-terminus.
bacteriophage T4 and vaccinia virus DNA ligases. The vaccinia
virus enzyme has 22% identical amino acids compared with the
putative ASFV DNA ligase. Identical residues are present along
the complete length of this region but are fewer at the extreme
carboxy termini. In addition, the conserved 16 amino acid motif
shared by vaccinia virus, yeast, and human DNA ligase I enzymes
adjacent to their carboxy termini is not present in ASFV DNA
ligase (13,27,31,32).
Assay for DNA ligase-AMP adduct formation
DNA ligases catalyze phosphodiester bond formation at single
strand breaks in double stranded DNA. The initial stage of the
joining reaction is the formation of a covalently linked enzyme-
adenylate intermediate with the simultaneous release of
pyrophosphate. The nucleotide derivative required for this
reaction has been shown to be either ATP for eukaryotic and
bacteriophage enzymes or NAD+ for bacterial enzymes (14).
Formation of this enzyme-adenylate intermediate can be
monitored by addition of a-[32P]-ATP to reactions followed by
analysis of protein products by SDS/PAGE and detection by
autoradiography. ASFV infected cell extracts were assayed for
proteins forming covalent interactions with [32P]-AMP. A
unique radio-labelled polypeptide of M, 45 kD was observed
after SDS/PAGE of ASFV-infected cell extracts prepared late
during infection were incubated with aZ-[32P]-ATP (fig 3a). No
such product was observed in mock-infected cell extracts. The
predicted molecular weight from the DNA ligase gene sequence
(48 kD) is similar to the size (Mr 45 kD) by SDS/PAGE of the
novel a-[32P]-ATP radio-labelled polypeptide. Formation of a
covalent protein-AMP adduct is not a common reaction (22) and
observation of such a radio-labelled polypeptide is indicative of
the presence of a DNA ligase enzyme. Further evidence that this
a-[32P]-ATP radio-labelled polypeptide is a DNA ligase-AMP
adduct was provided by addition of nicked DNA to the reaction
mixture. This resulted in loss of radioactivity from the polypeptide
as expected, due to the formation of a DNA-AMP intermediate
(data not shown). Our results also indicate that ATP rather than
NAD+ is used as co-factor, as might be predicted for the ASFV
polypeptide from the conserved active site region described
above. Direct evidence for the formation of an AMP-adduct with
the product of the ASFV DNA ligase gene was obtained by
transformation of E. coli BL2 1 pLysS with a plasmid containing
Table 2. Amino acid sequence comparison at the active sites of DNA ligases.
ASFV V H G K R N G V R A V A C
HUMAN C E Y K Y D G Q R A Q I H
S.POMBE C E Y K Y D G E R A Q V H
S.CEREVISIAE S E Y K Y D G E R A Q V H
PT3 A D C K Y D G V R G N I V
PT4 A Q L K A D G A R C F A E
PT6 A Q L K A D G A R C F A E
PT7 A E I K Y D G V R G N I C
VV A E V K Y D G E R V Q V H
The amino acid sequences surrounding the active site lysine of DNA ligases from
ASFV, human DNA ligase I (Human), S. pombe, S. cerevisiae, bacteriophage
T3, T4, T6 and T17 (PT3 to PT7) and vaccinia virus (VV) are shown (13,26-32).
Amino acids that are identical in all eukaryotic DNA ligases are shown in bold.
the putative ASFV DNA ligase gene (KS+lig) and incubation
of bacterial extracts with a-[32P]-ATP (fig 3b). A unique radio-
labelled polypeptide of M, 45 kD was detected in bacterial
extracts following transformation with KS+lig. No such product
was detected in extracts prepared from bacteria transformed with
plasmid KS+ lacking the ASFV DNA insert. This Mr 45 kD
polypeptide migrated with similar mobility to the a-[32P]-ATP
labelled DNA ligase-AMP product observed in ASFV-infected
cell extracts.
DISCUSSION
We have sequenced and identified an ASFV gene encoding a
polylypeptide of 419 amino acids with a predicted molecular
weight of 48 kD which has homology with DNA ligases.
A potential active site region containing a lysine residue
predicted to be involved in enzyme-adenylate adduct formation
is present in the ASFV polypeptide. Amino acid comparisons
across this region show that 3 out of 6 residues are identical and
that there is a conservative change of a fourth residue in the ASFV
DNA ligase compared with other DNA ligases (table 2). The
419 amino acid polypeptide encoded by ASFV shares
approximately 20% (bacteriophage T7) to 25% identity
(bacteriophages T3, 4 and 6) (26,28-30) over the complete
predicted amino acid sequence compared with other DNA ligases.
The amino terminal regions of all DNA ligases are diverse and
vary greatly in length and sequence. Identity increases to a
2670 Nucleic Acids Research, Vol. 20, No. 11
ASF MLSQFPGQCSNNVFCFPPIESETKNGKKASWI ICVQVMQHNTIL
ASF PITDEMFSTDVKDAVAEIFTKFFVEEGAVRISKTTRVTEGKNLGKKNATTVVH
ASF QAFKDALSKYNRHARQKRGAHTNRGMIPPMLVKYFNIIPKTFFEEETDPIVHG
ASF KRNGVRAVA CQQGD..GSI LLYSRTEKIF LaLD.NIKIC LKQLY.... L
Pt4 KadGaRcfA evrGDelddv rLlSRagnEy LGLD1.lKeF Likmtaearq
Vac lKvdGeRvqv hknnn... ef affSRnmKpv LshkvdylKZ ....Yipkaf
ASF FIDVRVYLDG ELYLB ...R. P.LQWPLQWI AGQANAA.. ..........
Pt4 ihpegVliDG ZLvyHeqvkK epegldflfd Ayp.NuKAke faevae-rta
Vac kkatsivLDs EivLvdehn. .... vPLpfg .lgihkl ... ..........
ASF .......... ...... DSSE LHFYVFDC ...... FWSDQL Ql... PSNKR
Pt4 angiankolk gtisekeaqc mkFqVwDyvp lveiyslpaf rlkydvrfsk
Vac .......... ... keykngn mclfVFDC ...... lyfDgf dNtdiPlyeR
ASF QQLLTNIFKQ KEDLTFIHQV ZNFSVKNZDS ALRLKTQFIK EGYZGAIVRN
Pt4 leqmTsgy.. .dkviil... lNqvVnNlD1 AkviykkyId qOlEGillkN
Vac rsfLkdvmve ipnrivfsel tNiS..NEsq ltdvlddalt rklZGlvlkd
ASF ANOPYEPG.. . YNNYHSPHL AKLKPLLDAE FILVD. .YTQ GKKGKDLGAI
Pt4 idGlwE .... ... NarSknL yKfKeviDvd lkiVg.iYph rKdptkaGgf
Vac iNGvYEPGkr rwlkikrdyL negsmadsAd lvvlgayYgk OaaOgimavf
ASF LWVC .. ELPN KKRFV............VTP KHLTYADRYA LFQILTPALF
Pt4 ilesecgkik vnagsglkdk agvksheldr trimenqnY. yigKilecec
Vac LmgCyddeeg KwktVtkcsg hddntlrVlq dqLTmvkink dpkKipewLv
ASF KKHLYGKELT VEYA....S..ISPKTGIPL ... QARAVGF R.
Pt4 ngwLksdgrT .dYv ...... kLflpiaIrL redktkAntF.
Vac vnkiYipdfv VEdpkqsqiw EiSgaeftss kehtAnqisi RfDrftrire
ASF ..... EPINV LEII
Pt4 .... edvfgd fhevtgl
Vac dktwkEsthl ndlvnltks
Figure 2. Amino acid comparison of ASFV DNA ligase with bacteriophage T4
and vaccinia virus DNA ligases aligned downstream from their predicted active
site lysine residues. The sequences downstream from the active site of the ASF,
T4 and VV DNA ligases were aligned using the programme GAP (20). The
complete amino acid sequence of ASFV DNA ligase is shown in upper case.
Amino acid residues identical between the ASFV sequence and one or both of
the other DNA ligase sequences are highlighted in bold upper case (13,29). The
conserved active site region leave the alignment is underlined. The 16 amino acid
peptide conserved at the carboxy termini of vaccinia virus, yeast and human DNA
ligase 1 (13,27,31,32) is also underlined.
maximum of 32% with bacteriophage T4 DNA ligase when just
the carboxy terminal amino acids downstream from the putative
active site lysine are compared (table 1). The conservation of
both the sequence at the carboxy termini of eukaryotic DNA
ligases and the distance between this conserved carboxy terminal
region and the active site lysine suggest that these features play
an important role in the function of the enzyme (25). Although
the level of identity between the ASFV and other known DNA
ligases is higher in the carboxy terminal region downstream from
the active site lysine residue, the carboxy terminus of the putative
ASFV DNA ligase is at least 44 amino acids shorter than the
other DNA ligases in this region (table 1) and does not contain
the highly conserved 16 amino acid sequence present in vaccinia
virus, yeast and human DNA ligase I enzymes (figure 2)
(13,27,31,32). This region is immunologically cross-reactive
between vaccinia and mammalian cell DNA ligases (33). The
shorter length of the putative ASFV DNA ligase carboxy terminal
region compared with other DNA ligases may indicate differences
in enzyme function, specificity in DNA binding or in targeting
of the enzyme within cells. In particular, cellular DNA ligases
function in the nucleus, whereas the ASFV DNA ligase probably
functions in the cytoplasm and therefore may not contain a nuclear
targeting signal. However, the C-terminal conserved basic region
is not sufficient to dictate nuclear localization in vaccinia virus-
infected cells since the vaccinia DNA ligase which contains this
region is located in cytoplasmic virus factories. Perhaps when
removed from the context of a virus infection the vaccinia enzyme
becomes partially nuclear and this might explain the ability of
vaccinia virus DNA ligase to complement a yeast mutant (33).
- 30}
Fiure 3. (a) ASFV DNA ligase-AMP addLct formaion in thecysm ofASFV
infected cells. Cytoplasmic extracts were prepared from ASFV-infected cells at
various times post infection (21). Extracts were incubated with f-[I32P]-ATP (22)
and labelled products detcted by SDS/PAGE and autoradiography of dried gels.
Lane (a) uninfected cell extract, lane (b) ASFV infected cell extract 4 hours post
infection, lane (c) ASFV infected cell extract 16 hours post infection. Lane (d)
T4 DNA ligase and lane (e) vaccinia virus infected cell extract. The positions
of molecular weight markers are shown in kD. (b) Expression of ASFV DNA
ligase in E. coli BL21 pLysS. E. coli BL21 pLysS (23) were transformed with
bluescript KS+ or KS+lig DNA containing the ASFV DNA ligase gene under
the control of the T7 RNA polymerase promoter. Expression of the ASFV gene
was induced by the addition of 2mM IPITG to cultures. Bacterial extracts were
prepared by sonication, incubated with a-[32P]-ATP (22) and labelled products
detected by SDS/PAGE and autoradiography of dried gels. Lane (a) E. coli BL21
pLysS transformed with KS+ and lane (b) E. coli BL21 pLysS transformed with
KS+lig DNA. The positions of molecular weight markers are shown in kD.
The ASFV DNA ligase is the smallest eukaryotic DNA ligase
yet identified and it remains possible that it may be more highly
homologous to the as yet uncloned mammalian DNA ligases H
and Im (34).
ASFV DNA ligase [32P]-AMP-adduct formation is detectable
late in infection, although it is not yet known when transcription
of this ASFV gene occurs. The vaccinia DNA ligase enzyme
initiation codon forms part of a late transcriptional initiation
sequence (13), however, the gene is transcribed early and the
enzyme appears to accumulate at late times, implying stability
of the protein. The nucleotide sequence upstream of the ASFV
DNA ligase gene start codon does not contain obvious homology
with the well documented vaccinia virus early or late promoter
regions (35,36) although it has been suggested that some ASFV
promoters may be similar to those of poxviruses (37). However,
two regions containing a high proportion of A-residues are present
Ai B ('' I) I'
69
-- 464U
- 3O
I1 "X
- 69
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upstream of the ASFV DNA ligase gene at positions -3 to -7
and -30 to -36 with respect to the ATG. It is possible that
one or both of these regions may be analogous to a critical
vaccinia virus early promoter region thought to be required for
the binding of a transcription factor (35). No homology with
either the eukaryotic polyadenylation signal (AATAAA) or the
vaccinia virus early termination signal (TTTTTNT) (38,39) is
apparent within the nucleotide sequence adjacent to the stop codon
of the ASFV ligase gene.
The conservation of the active site lysine and surrounding
sequences and the identification of a Mr 45 kD protein with
AMP-binding activity in cytoplasmic extracts of ASFV infected
cells is consistent with the DNA ligase being functional. The
presence of an ASFV encoded DNA ligase was predicted (13)
since ASFV replicates in the cytoplasm of infected cells. This
enzyme may be involved in the replication, repair or
recombination of viral DNA. Vaccinia virus DNA ligase is not
essential for viral replication or recombination in vitro (40,41),
although it does play an important role in vivo (33), and DNA
ligase negative virus has an increased sensitivity to DNA
damaging agents in vitro.
Very little is known about the mechanism of ASFV DNA
replication, which occurs in the cytoplasm approximately mid-
way through the infection cycle. The genome structure of ASFV
and poxviruses is similar and consists of linear double stranded
DNA closed by terminal hairpin loops which are present in two
forms that are inverted and complementary with respect to each
other. Head to head concatameric forms of DNA are also found
in both ASFV and vaccinia virus infected cells (42,43), and thus,
it is probable that the mechanism of ASFV DNA replication is
similar to that utilised by the poxviruses. Two basic models have
been proposed for poxviral DNA replication (reviewed in 44).
The simplest model comprises unidirectional synthesis after a nick
is introduced at one or both ends of the genome in the terminal
hairpin(s) followed by self-priming at the free 3' ends. This
mechanism does not require a DNA ligase, as a nicking-joining
enzyme (45) is capable of creating and sealing the necessary
breaks in the DNA. A second model suggests leading and lagging
strand synthesis. After the introduction of nick(s) and self-priming
at the hairpin termini, DNA synthesis would proceed along both
DNA strands. Okazaki-like fragments formed on the lagging
strand would then require joining by a DNA ligase. Since vaccinia
virus DNA ligase is not essential for virus replication in tissue
culture cells, the first of these mechanisms is more likely, unless
the vaccinia enzyme is complemented by cellular DNA ligase
I (33), or by the immunologically unrelated DNA ligase II or
III (34).
Genetic recombination between the genomes of orthopoxviruses
is well documented (46-49) and genetic recombination between
capripoxviruses during natural transmission has been suggested
(50). Recombination between ASF viruses has also been
demonstrated in vitro (51), and therefore, it is possible that
poxvirus and ASFV DNA ligases augment the generation of
recombinant viruses in the field. A function for these DNA ligases
in either DNA recombination or repair could denote an
instrumental role in viral evolution.
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